AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
AstraZeneca plans to submit baxdrostat for regulatory review by the end of 2025, aiming for potential approvals in 2026 starting in the U.S. and EU. Baxdrostat inhibits aldosterone, tackling a hormonal driver of hypertension rather than just symptoms.
In advanced trial results presented at a medical meeting, 2 mg baxdrostat added to standard therapy cut systolic BP by 9.8 mmHg (placebo-adjusted) at 12 weeks; 1 mg cut 8.7 mmHg. Investigators noted hyperkalaemia in ~1.1% of patients. AstraZeneca estimates >$5B peak sales, while rival lorundrostat (Mineralys) recently showed a 9.1 mmHg reduction at six weeks. Unmet need in resistant hypertension remains high worldwide.
You May Interested In
2026-07-26
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Titan Technology Makes Bold Move with 55.85 Million Yuan Acquisition of UK Biochemical Firm ASL — What's Behind the Deal?
-
Kering and L'Oréal Form $4 Billion Strategic Alliance in Luxury Beauty and Wellness
-
Wanhua Chemical's Hungarian 650,000-ton MDI/TDI Plant to Shut Down for 35-Day Maintenance
-
Beiersdorf Delivers 2025 Growth Despite Ongoing Market Pressure
-
Yulong Petrochemical’s 100,000-ton MMA Project Comes Online Amid a “Deep V-Shaped Rebound” — Opportunity or Hidden Risk?
-
BASF Battles Market Turmoil as Profits Slide
-
Cadmium Sulfide Uses: Pigments, Semiconductors & Safety Tips
-
Symrise Launches “Care & Wellness” Division to Strengthen Beauty–Health Integration
-
IMCD to Acquire 100% of Italian Coatings Distributor Tillmanns
-
China National Salt Industry Corporation Advances 10,000 t/y Sodium Metal Expansion Project, Industry Leader Invests Nearly RMB 100 Million
Recommend Reading
-
IMCD Acquires Dong Yang FT, Entering the Korean Beauty Sector
-
Procter & Gamble Posts Higher Profits on Strong Personal Care Sales and Recovery in China
-
“Falling Revenue, Soaring Profits”: Is AkzoNobel’s Financial Alchemy Real Muscle—or Just Smoke and Mirrors?
-
Fracturing the Crown: BASF Antwerp’s 600-Job Cut and the Global Alarm
-
Givaudan to Build New Fragrance Compounding Facility in Pedro Escobedo, Mexico
-
Low Demand and Low Inventory for Formic Acid Go Hand in Hand
-
Crude Oil Prices Rise, Local Refinery Gas and Diesel Prices in China Increase Slightly
-
Costs Decline, Supply Remains Abundant—DOP Prices Fluctuate and Fall This Week
-
Strong upward trend in the Chinese soda ash market
-
Supply Strong, Demand Weak: ABS Prices Fall in Mid-August in China